首页>
外国专利>
NEW INDICATIONS FOR THE USE OF MANNAN-BINDING LECTIN IN THE TREATMENT OF IMMUNO-COMPROMISE INDIVIDUALS
NEW INDICATIONS FOR THE USE OF MANNAN-BINDING LECTIN IN THE TREATMENT OF IMMUNO-COMPROMISE INDIVIDUALS
展开▼
机译:使用甘露聚糖结合的凝集素治疗免疫缺陷个人的新适应症
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and/or treatment of infection. In particular the invention relates to prophylaxis and/or treatment of infection in an individual having an immunocompromised condition; and/or an individual being at risk of acquiring an immunocompromised condition resulting from a medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of infection in individuals suffering from neutropenia, in particular as prophylaxis and/or treatment of infection in individuals receiving or going to receive chemotherapy or similar treatment. The individuals may be treated independent on their serum MBL level, and it has been shown that in particular individuals having a serum MBL level in the range of from 50 ng/ml serum to 500 ng/ml serum may benefit from the prophylaxis and/or treatment.
展开▼